Inj. K MM2 mg/0.2 ml

Inj. K MM is a fat-soluble vitamin (Vitamin K1) used to prevent and treat bleeding problems that result from low levels of vitamin K-dependent clotting factors.

Established/Approved Uses

• Prevention of hemorrhagic disease of the newborn (HDN): routine prophylactic administration to newborns shortly after birth, as recommended by pediatric guidelines.
• Treatment of hemorrhagic disease of the newborn and vitamin K deficiency bleeding in infants.
• Hypoprothrombinemia caused by vitamin K deficiency or interference with vitamin K activity, including reversal of excessive anticoagulant effect of warfarin and other vitamin K antagonists (coumarin-type anticoagulants).
• Vitamin K deficiency due to malabsorption (e.g. biliary obstruction, celiac disease, cystic fibrosis, chronic diarrhea) or other conditions limiting vitamin K absorption/synthesis.

Adjunct / Supportive Use

• As part of supportive management in patients on prolonged broad-spectrum antibiotic therapy or parenteral nutrition who develop vitamin K deficiency.

Use of Inj. K MM should always be guided by a physician, particularly when it is being used to reverse anticoagulation, since this may affect ongoing anticoagulant therapy.

Each formulation of Phytomenadione contains phytomenadione (vitamin K1) as the active ingredient. Common presentations include:

• Injection (IM/IV/SC use): commonly available as ampoules containing 10 mg/mL, and pediatric/neonatal ampoules containing 1 mg/0.5 mL or 2 mg/0.2 mL.
• Oral tablets: commonly available containing 10 mg of phytomenadione.

Exact strength and available dosage forms may vary by manufacturer; refer to the specific product label.

Inj. K MM is the pharmaceutical name for phylloquinone, the naturally occurring form of vitamin K found in plants. It is a fat-soluble vitamin that the liver requires to synthesize several proteins essential for normal blood clotting.

Vitamin K deficiency can occur in newborns (whose vitamin K stores are naturally low at birth), in people with fat malabsorption disorders, in those on long-term antibiotics, and in patients who have taken an excessive dose of a vitamin K antagonist anticoagulant such as warfarin. Inj. K MM corrects this deficiency by restoring the vitamin K needed for normal coagulation factor production.

Inj. K MM belongs to the therapeutic class of Vitamin K preparations / antihemorrhagic agents (coagulation factor synthesis-promoting vitamins).

Phytomenadione (vitamin K1) is an essential cofactor for a hepatic carboxylase enzyme that converts specific glutamic acid residues on clotting factors II (prothrombin), VII, IX, and X, as well as the anticoagulant proteins C and S, into their biologically active gamma-carboxyglutamate (Gla) forms.

Without adequate vitamin K, the liver produces non-functional (undercarboxylated) clotting factors, resulting in a bleeding tendency and a prolonged prothrombin time (PT/INR). By supplying vitamin K, Phytomenadione allows the liver to resume synthesis of functional clotting factors, correcting the coagulation defect and, in the context of vitamin K antagonist (e.g., warfarin) therapy, reversing excessive anticoagulation. The onset of effect is not immediate, since it depends on synthesis of new clotting factors: some improvement in coagulation is typically seen within a few hours after oral or parenteral administration, with fuller correction over 12-24 hours.

Inj. K MM may be given orally, or by intramuscular (IM), subcutaneous (SC), or intravenous (IV) injection, depending on the clinical situation.

• Oral tablets may be taken with or without food.
• Injectable Inj. K MM must be prepared and administered by a trained healthcare professional.
• If IV administration is necessary, it must be given slowly (diluted in a compatible IV fluid, infused over several minutes), never as a rapid bolus, due to the risk of anaphylactoid reactions.

Vitamin K antagonist anticoagulants (warfarin and other coumarin derivatives): Inj. K MM directly antagonizes and reverses the anticoagulant effect of these drugs. This is the intended mechanism when Inj. K MM is used to treat excessive anticoagulation or warfarin overdose, but in a patient who needs to remain therapeutically anticoagulated, administration of Inj. K MM will reduce or reverse that needed anticoagulant effect. For this reason, the dose and route of Inj. K MM used for reversal must be carefully individualized (often using the lowest effective dose) so that the patient can be safely re-anticoagulated later if ongoing anticoagulation is still required.

Mineral oil and orlistat (and other agents that reduce fat absorption): may reduce the intestinal absorption of oral Inj. K MM, potentially reducing its effectiveness.

Broad-spectrum antibiotics: prolonged use can reduce vitamin K-producing gut flora and may increase vitamin K requirements or potentiate anticoagulant effects, indirectly affecting the response to Inj. K MM.

Most side effects of Inj. K MM are mild and related to the injection site; serious reactions are rare but can occur, particularly with intravenous use.

• Common: pain, redness, swelling, or tenderness at the injection site (IM/SC use); a transient "peculiar" taste (oral).
• Uncommon: flushing, dizziness, or mild hypotension, more often reported with IV administration.
• Rare but serious: anaphylactoid/anaphylactic reactions (including flushing, chest tightness, dyspnea, cyanosis, hypotension, cardiac/respiratory arrest), reported particularly with rapid IV injection and occasionally fatal — see Precautions and Warnings.
• Rare (neonates): hyperbilirubinemia has been reported historically with high or repeated doses of vitamin K in newborns, particularly preterm infants.

Inj. K MM (vitamin K1) is generally considered safe for use during pregnancy when clinically indicated, and it is standard practice to give it to newborns immediately after birth to prevent hemorrhagic disease of the newborn. Nonetheless, as with any medicine in pregnancy, Inj. K MM should be used only if clearly needed and the potential benefit justifies any potential risk; use should be under the guidance of a physician.

Inj. K MM is compatible with breastfeeding at recommended doses; it is naturally present in breast milk in small amounts, and maternal or infant supplementation should still be guided by a physician's advice regarding dose and necessity.

Risk of severe reactions with intravenous administration: Rare but serious and occasionally fatal anaphylactoid reactions (resembling anaphylaxis, with flushing, dyspnea, chest pain, hypotension, and cardiovascular collapse) have been reported with intravenous Inj. K MM, particularly following rapid injection. Because of this, the intramuscular, subcutaneous, or oral route should be used whenever clinically appropriate; if the IV route is unavoidable, Inj. K MM must be diluted and given as a slow infusion, with the patient monitored during and after administration.

Hepatic impairment: in patients with significant liver disease, the coagulation defect may not be fully corrected by Inj. K MM because the liver's ability to synthesize clotting factors is itself impaired; response should be assessed with follow-up coagulation testing.

Ongoing anticoagulation needs: in patients who require continued therapeutic anticoagulation, use of Inj. K MM to correct an elevated INR should be dose-individualized to avoid unnecessarily reversing needed anticoagulant therapy (see Interactions).

Repeated high doses in neonates: caution is advised with repeated or excessive dosing in newborns, especially preterm infants, due to a historical association between high vitamin K doses and hyperbilirubinemia.

Overdose or excessive dosing with Inj. K MM is uncommon but may transiently interfere with the effectiveness of vitamin K antagonist anticoagulants (making a patient resistant to re-anticoagulation for some time) and, in neonates, has been associated with a risk of hyperbilirubinemia. Symptoms of a serious reaction (particularly after IV use) may include flushing, breathing difficulty, chest tightness, or a drop in blood pressure.

If an overdose or a serious reaction is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt to manage a suspected overdose or severe reaction at home.

Store at room temperature (below 30°C), protected from light and moisture, as Inj. K MM is a light-sensitive compound. Keep out of reach of children.

Neonates/Infants: Inj. K MM is standard of care for prevention of hemorrhagic disease of the newborn, given as a single dose shortly after birth per pediatric guidelines; treatment doses for bleeding are individualized by weight.

Children: dosing is individualized based on age, weight, and severity of vitamin K deficiency or bleeding, under pediatric supervision.

Elderly: no specific dose adjustment is established based on age alone, but elderly patients on anticoagulant therapy should have their dose individualized carefully and their coagulation status monitored.

Hepatic impairment: response may be reduced; see Precautions and Warnings.

Renal impairment: no well-established dose adjustment is required.

For prevention of hemorrhagic disease of the newborn, Inj. K MM is typically given as a single dose at birth. For treatment of bleeding due to vitamin K deficiency or anticoagulant reversal, treatment duration and repeat dosing are guided by clinical response and coagulation test results (PT/INR), and may range from a single dose to several days of therapy. For chronic malabsorption-related deficiency, longer-term or repeated dosing may be required as directed by a physician.

Phytomenadione belongs to the drug class of Vitamin K1 (phylloquinone) preparations, also categorized under antihemorrhagic/hemostatic vitamins.

Phytomenadione acts as an essential cofactor for the hepatic enzyme gamma-glutamyl carboxylase, which converts inactive precursor clotting factors II, VII, IX, and X (and proteins C and S) into their active, gamma-carboxylated forms capable of binding calcium and participating in the coagulation cascade. By replenishing vitamin K, Phytomenadione restores the liver's ability to produce functional clotting factors, correcting bleeding tendencies caused by vitamin K deficiency or by vitamin K antagonist drugs.

C

Inj. K MM is well established and widely recommended for routine prophylaxis of hemorrhagic disease of the newborn, given as a single intramuscular dose (typically 0.5-1 mg) shortly after birth, per pediatric society guidance.

For treatment of vitamin K deficiency bleeding beyond the neonatal period, dosing of Inj. K MM is individualized by a pediatrician based on the child's weight, age, and severity of the bleeding tendency. Safety and efficacy of repeated high-dose use in preterm or very low birth weight infants require particular caution due to the historical association between high vitamin K doses and hyperbilirubinemia in this population.